Synedgen, Inc.
Claremont, CA
- UEI
- HX79BD6YQ521
- CAGE
- 5JGC8
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1420 N Claremont Blvd #105d, Claremont, CA 91711, USA
- Website
- synedgen.com
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $1,891,200 |
| FY2024 | $19,234,879 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| The Trustees Of Columbia University In The City Of New York | U01AI172853 | $53,411 |
Similar vendors
About the company
Synedgen, Inc. is a for-profit corporate entity registered in SAM.gov, specializing in regenerative medicine, wound healing, and advanced pharmaceutical research and development. Located in Claremont, California, the company focuses on developing innovative medical technologies and drug products that address complex medical challenges, particularly in the areas of radiation injury mitigation, gastrointestinal health, and tissue repair. As a small business, Synedgen has established itself as a strategic partner for federal agencies seeking cutting-edge biomedical solutions.
Through federal contract awards, Synedgen has secured multiple significant contracts from agencies including the Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) and the Defense Health Agency (DHA). These contracts, predominantly set aside for small businesses, center on developing advanced medical technologies to prevent and mitigate radiation-induced injuries. Notable contract work includes a $119,642,445 contract to develop PAAG17G (MIIST305), an orally administered drug designed to reduce mortality and morbidity from acute ionizing radiation exposure, and a $2,297,415 SBIR Phase III contract to develop field-stable glycopolymer-mimicking polysaccharides for preventing radiation or nuclear injury. The company has also received a $549,725 contract from the Department of the Army Medical Command to develop technologies controlling scar formation after burn injuries.
In the realm of federal grants, Synedgen has been involved in both prime and sub-grant awards focused on advanced medical research. A prime federal grant from the Defense Health Agency (Award ID: W81XWH2210869) supports research on developing glycopolymer-mimicking polysaccharides to restore gastrointestinal integrity in inflammatory bowel diseases. Additionally, the company serves as a critical subrecipient in a grant awarded to Columbia University, where Synedgen's role involves synthesizing their proprietary therapeutic MIIST305 under good manufacturing practices, consulting on experimental protocols, and providing scientific feedback. These grant activities demonstrate Synedgen's expertise in developing sophisticated medical interventions, particularly in areas of gastrointestinal health, radiation mitigation, and regenerative medicine.
Quick answers
Is Synedgen, Inc. registered in SAM.gov?
Yes. Synedgen, Inc.'s SAM.gov registration is active through November 11, 2026.
What is Synedgen, Inc.'s CAGE code?
Synedgen, Inc.'s CAGE code is 5JGC8, and its Unique Entity ID (UEI) is HX79BD6YQ521.
How much has Synedgen, Inc. received in federal contracts?
Federal contracts obligated $1,891,200 to Synedgen, Inc. in fiscal year 2025 and $21,126,079 in fiscal years 2023 through 2027.
How does Synedgen, Inc. rank among federal contractors?
Synedgen, Inc. ranked #66 in PSC AN13 in FY2025.
What is Synedgen, Inc.'s most recent federal award?
Synedgen, Inc.'s most recent federal contract award is Advance the development of PAAG17G (drug product: MIIST305), a once daily, orally administered, GUT-restricted drug, to… (75A50124C00047), from Office of the Assistant Secretary for Preparedness and Response, on September 30, 2024.
On GovTribe
See Synedgen, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors